3.1 Subject disposition and baseline characteristics
There were 18 subjects enrolling in this study. All 18 subjects completed the phase of a single dose of SHR2554 and the phase of multiple doses of rifampin. 17 subjects completed the coadministration of SHR2554 and rifampin, and 1 subject withdrew from the study due to AEs. All 18 subjects who received investigation drug were included in the safety set and PK concentration set. The subject disposition and baseline characteristics were shown in Table 1.